# STOP-HER2 (NCT05721248)

> STOP-HER2: Stopping Trastuzumab in HER2+ MBC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05721248
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Dana-Farber Cancer Institute
- Conditions: Breast Cancer; Metastatic Breast Cancer; HER2-positive Breast Cancer
- Interventions: Cessation of anti-HER2 treatment
- Enrollment: 82
- Primary outcome: 1-year progression-free survival (PFS) Stopped Anti-HER2 Treatment
- Primary outcome: 1-year progression-free survival (PFS) Continued Anti-HER2 Treatment

## Indexed commentary on STOP-HER2 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 11
- X threads: 5
- Podcasts: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=stop-her2-nct05721248

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05721248", "email": "<work email>"}; the inbox owner confirms by the emailed link.